321 related articles for article (PubMed ID: 26912802)
21. The role of fluorescence in situ hybridization and gene expression profiling in myeloma risk stratification.
Hose D; Seckinger A; Jauch A; Rème T; Moreaux J; Bertsch U; Neben K; Klein B; Goldschmidt H
Srp Arh Celok Lek; 2011 Dec; 139 Suppl 2():84-9. PubMed ID: 22352188
[TBL] [Abstract][Full Text] [Related]
22. An abnormal nonhyperdiploid karyotype is a significant adverse prognostic factor for multiple myeloma in the bortezomib era.
Tan D; Teoh G; Lau LC; Lim A; Lim TH; Yap KC; Premalatha P; Lao ZT; Wee N; Choo C; Wee HC; Su S; Lee YS; Lee LH; Hwang W; Goh YT
Am J Hematol; 2010 Oct; 85(10):752-6. PubMed ID: 20721886
[TBL] [Abstract][Full Text] [Related]
23. Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: web-based multicenter registry study.
Oh S; Koo DH; Kwon MJ; Kim K; Suh C; Min CK; Yoon SS; Shin HJ; Jo DY; Kwak JY; Kim JS; Sohn SK; Joo YD; Eom HS; Kim SH; Kim YS; Kim C; Mun YC; Kim H; Lee DS; Lee JH;
Ann Hematol; 2014 Aug; 93(8):1353-61. PubMed ID: 24671365
[TBL] [Abstract][Full Text] [Related]
24. Incorporation of the bone marker carboxy-terminal telopeptide of type-1 collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma.
Jakob C; Sterz J; Liebisch P; Mieth M; Rademacher J; Goerke A; Heider U; Fleissner C; Kaiser M; von Metzler I; Müller C; Sezer O
Leukemia; 2008 Sep; 22(9):1767-72. PubMed ID: 18580957
[TBL] [Abstract][Full Text] [Related]
25. Combination of Genetic Aberration With International Staging System Classification for Stratification of Asian Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation.
Byun JM; Kim D; Shin DY; Kim I; Koh Y; Yoon SS
In Vivo; 2019; 33(2):611-619. PubMed ID: 30804149
[TBL] [Abstract][Full Text] [Related]
26. Cytogenetics and Revised International Staging System (R-ISS): Risk Stratification in Multiple myeloma - A Retrospective Study in Indian Population.
Udupa CBK; Udupa KS; Pai A; Sherigar P
Iran J Pathol; 2020; 15(3):182-188. PubMed ID: 32754213
[TBL] [Abstract][Full Text] [Related]
27. Can genome array screening replace FISH as a front-line test in multiple myeloma?
Boneva T; Brazma D; Gancheva K; Howard-Reeves J; Raynov J; Grace C; Nacheva EP
Genes Chromosomes Cancer; 2014 Aug; 53(8):676-92. PubMed ID: 24757046
[TBL] [Abstract][Full Text] [Related]
28. Hyperhaploidy is a novel high-risk cytogenetic subgroup in multiple myeloma.
Sawyer JR; Tian E; Shaughnessy JD; Epstein J; Swanson CM; Stangeby C; Hale CL; Parr L; Lynn M; Sammartino G; Lukacs JL; Stein C; Bailey C; Zangari M; Davies FE; Van Rhee F; Barlogie B; Morgan GJ
Leukemia; 2017 Mar; 31(3):637-644. PubMed ID: 27694925
[TBL] [Abstract][Full Text] [Related]
29. Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients with multiple myeloma: a single center experience on 228 patients.
Moulopoulos LA; Dimopoulos MA; Kastritis E; Christoulas D; Gkotzamanidou M; Roussou M; Koureas A; Migkou M; Gavriatopoulou M; Eleutherakis-Papaiakovou E; Gika D; Koutoulidis V; Terpos E
Am J Hematol; 2012 Sep; 87(9):861-4. PubMed ID: 22641455
[TBL] [Abstract][Full Text] [Related]
30. Chromosomal aberrations in 130 patients with multiple myeloma studied by interphase FISH: diagnostic and prognostic relevance.
Schmidt-Wolf IG; Glasmacher A; Hahn-Ast C; Jüttner A; Schnurr T; Cremer F; Moehler T; Goldschmidt H; Busert B; Schubert R; Schwanitz G
Cancer Genet Cytogenet; 2006 May; 167(1):20-5. PubMed ID: 16682281
[TBL] [Abstract][Full Text] [Related]
31. A retrospective analysis of cytogenetic and clinical characteristics in patients with multiple myeloma.
He J; Yang L; Meng X; Wei G; Wu W; Han X; Zheng G; Zheng W; Ye X; Shi J; Xie W; Zhang J; Huang H; Lin M; Cai Z
Am J Med Sci; 2013 Feb; 345(2):88-93. PubMed ID: 22986611
[TBL] [Abstract][Full Text] [Related]
32. 99mTc-sestamibi imaging and bone marrow karyotyping in the assessment of multiple myeloma and MGUS.
Giovanella L; Taborelli M; Ceriani L; Zucca E; Cavalli F; Delaloye AB
Nucl Med Commun; 2008 Jun; 29(6):535-41. PubMed ID: 18458600
[TBL] [Abstract][Full Text] [Related]
33. Genomic studies of multiple myeloma reveal an association between X chromosome alterations and genomic profile complexity.
Sticca T; Caberg JH; Wenric S; Poulet C; Herens C; Jamar M; Josse C; El Guendi S; Max S; Beguin Y; Gothot A; Caers J; Bours V
Genes Chromosomes Cancer; 2017 Jan; 56(1):18-27. PubMed ID: 27454822
[TBL] [Abstract][Full Text] [Related]
34. Cytogenetic classification in Korean multiple myeloma patients: prognostic significance of hyperdiploidy with 47-50 chromosomes and the number of structural abnormalities.
Lim JH; Seo EJ; Park CJ; Jang S; Chi HS; Suh C; Kim H; Kim SR
Eur J Haematol; 2014 Apr; 92(4):313-20. PubMed ID: 24372944
[TBL] [Abstract][Full Text] [Related]
35. Sequential analysis of chromosome aberrations in multiple myeloma during disease progression.
Wu KL; Beverloo B; Velthuizen SJ; Sonneveld P
Clin Lymphoma Myeloma; 2007 Jan; 7(4):280-5. PubMed ID: 17324335
[TBL] [Abstract][Full Text] [Related]
36. Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma.
Mellors PW; Binder M; Ketterling RP; Greipp PT; Baughn LB; Peterson JF; Jevremovic D; Pearce KE; Buadi FK; Lacy MQ; Gertz MA; Dispenzieri A; Hayman SR; Kapoor P; Gonsalves WI; Hwa YL; Fonder A; Hobbs M; Kourelis T; Warsame R; Lust JA; Leung N; Go RS; Kyle RA; Rajkumar SV; Kumar SK
Blood Adv; 2020 May; 4(10):2236-2244. PubMed ID: 32442300
[TBL] [Abstract][Full Text] [Related]
37. High detection rate of clinically relevant genomic abnormalities in plasma cells enriched from patients with multiple myeloma.
Stevens-Kroef M; Weghuis DO; Croockewit S; Derksen L; Hooijer J; Elidrissi-Zaynoun N; Siepman A; Simons A; Kessel AG
Genes Chromosomes Cancer; 2012 Nov; 51(11):997-1006. PubMed ID: 22833442
[TBL] [Abstract][Full Text] [Related]
38. Multiple myeloma staging based on the combination of beta-2-microglobulin and albumin: the role of albumin in the model.
Mihou D; Katodritou E; Zervas K
Hematology; 2007 Dec; 12(6):527-31. PubMed ID: 17852450
[TBL] [Abstract][Full Text] [Related]
39. [Molecular cytogenetic analyses of patients with plasma cell myeloma in Tolna and Baranya counties in Hungary].
Kosztolányi S; Horváth B; Hosnyánszki D; Kereskai L; Sziládi E; Jáksó P; Alizadeh H; Szuhai K; Alpár D; Kajtár B
Orv Hetil; 2019 Jun; 160(24):944-951. PubMed ID: 31433233
[TBL] [Abstract][Full Text] [Related]
40. Cytogenetic and molecular aberrations of multiple myeloma patients: a single-center study in Singapore.
Lim AS; Lim TH; See KH; Ng YJ; Tan YM; Choo NS; Lim SX; Yee Y; Lau LC; Tien SL; Sathish K; Tan DC
Chin Med J (Engl); 2013; 126(10):1872-7. PubMed ID: 23673102
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
